Applications including "Draft"

LB902 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB901 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB900 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustain C8
LB899 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustainSwift C18
GA352 - Analysis of Dipropylene Glycol -

GC InertSearch InertCap WAX-HT
LB896 - Analysis of Triptorelin Pamoate -

LC InertSearch InertSustain C18
LB895 - Analysis of Venlafaxine hydrochloride -

LC InertSearch InertSustainSwift C8
LB891 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18 HP
LB890 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18 HP
LB889 - Analysis of Propyl gallate -

LC InertSearch Inertsil WP300
LB888 - Analysis of Propyl gallate -

LC InertSearch Inertsil WP300
LB887 - Analysis of Propyl gallate -

LC InertSearch Inertsil ODS-4
LB885 - Analysis of Voriconazole -

LC InertSearch InertSustain C18
LB884 - Analysis of Voriconazole -

LC InertSearch InertSustain C18
LB882 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch InertSustain C18
LB881 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB880 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch InertSustain C18
LB879 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB878 - Analysis of Mefenamic acid -

LC InertSearch InertSustain C18
LB877 - Analysis of Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB874 - Analysis of Captopril and Captopril Disulfide -

LC InertSearch InertSustain AQ-C18
LB873 - Tacrolimus Extended-Release Capsules -

LC InertSearch InertSustain AQ-C18
LB872 - Analysis of Febuxostat -

LC InertSearch InertSustain Phenyl
LB871 - Analysis of Febuxostat -

LC InertSearch InertSustain Phenyl
LB870 - Analysis of Febuxostat -

LC InertSearch InertSustain Phenyl
LB867 - Analysis of Febuxostat -

LC InertSearch InertSustain C18
LB849 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LC InertSearch Inertsil ODS-4
LB848 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LC InertSearch Inertsil ODS-4
LB755 - Analysis of Oxaliplatin (Under the Condition of the draft for the Japanese Pharmacopoeia18th supplement II) -

LC InertSearch InertSustainSwift C18
LB671 - Analysis of Sucrose (Under the condition of the PDG (Pharmacopeial Discussion Group) Stage 2 Drafts) -

LC InertSearch InertSphere Sugar-2
LB670 - Analysis of Sucrose (Under the condition of the PDG (Pharmacopeial Discussion Group) Stage 2 Drafts) -

LC InertSearch InertSphere Sugar-2
LB641 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LC InertSearch InertSustain C18
LB640 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LC InertSearch InertSustain C18
LB635 - Analysis of Levetiracetam (Under the Condition of draft for USP) -

LC InertSearch InertSustain AQ-C18 HP
LB634 - Analysis of Rivaroxaban (Under the Condition of draft for USP, Rivaroxaban Tablets) -

LC InertSearch InertSustainSwift C18
LB633 - Analysis of Rivaroxaban (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB628 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (7) 2-Pyrrolidone) -

LC InertSearch Inertsil ODS-3
LB627 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone and vinyl acetate) -

LC InertSearch Inertsil ODS-4
LB624 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LC InertSearch InertSustain Phenyl
LB623 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LC InertSearch InertSustain Phenyl
LT130 - Analysis of Anion Surfactants by LC/MS/MS -

LC Technical Note InertSustain C18 HP Inertsil C8-4 HP
LT052 - Analysis of Geniposide with a Photodiode Array Detection -

LC Technical Note Inertsil ODS-SP
LB555 - Analysis of Mirtazapine (Under the Condition of draft for USP, Mirtazapine Compounded Oral Suspension, Veterinary) -

LC InertSearch Inertsil ODS-3
LB548 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB547 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB546 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB545 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB532 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets B) -

LC InertSearch InertSustain C18
LB531 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets A) -

LC InertSearch InertSustain C18
LB529 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc Granules) -

LC InertSearch InertSustain C18
LB528 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc) -

LC InertSearch InertSustain C18
LB527 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LC InertSearch Inertsil ODS-4
LB526 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LC InertSearch Inertsil ODS-4
LB525 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB523 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB520 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C18
LB519 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C18
LB512 - Analysis of Pioglitazone hydrochloride （Under the Condition of the draft for USP） -

LC InertSearch InertSustain C18
LB510 - Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) -

LC InertSearch InertSustainSwift C18
LB508 - Analysis of Sitagliptin (Under the Condition of the draft for the Japanese Pharmacopoeia, Sitagliptin Phosphate Hydrate) -

LC InertSearch InertSustain Cyano
LB489 - Analysis of Azosemide (Under the Condition of the draft for the Japanese Pharmacopoeia, Azosemide Tablets) -

LC InertSearch InertSustain C18
LB476 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch Inertsil Ph
LB475 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch Inertsil Ph-3
LB474 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch InertSustain Phenylhexyl
LB473 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch InertSustain Phenyl
LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C8
LB471 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB448 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) -

LC InertSearch InertSustain C8
LB447 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) -

LC InertSearch InertSustainSwift C18 HP
LB446 - Analysis of Hydrocortisone butyrate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3 HP
LB444 - Analysis of Pazufloxacin mesilate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-2
LB415 - Analysis of Methotrexate (Under the Condition of the draft for the Japanese Pharmacopoeia, Methotrexate Tablets) -

LC InertSearch Inertsil ODS-4
LB413 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB412 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB411 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB410 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB409 - Analysis of Mesalazine (Under the Condition of the draft for the Japanese Pharmacopoeia, Mesalazine Extended-release Tablets) -

LC InertSearch Inertsil ODS-4
LB177 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 2-pyrrolidone) -

LC InertSearch InertSustain C18
LB176 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone) -

LC InertSearch InertSustain C18
LB106 - Analysis of Pitavastatin calcium tablets (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
GA275 - Analysis of Hydroxypropyl Cellulose(Under the Condition of the draft for the Japanese Pharmacopoeia) -

GC InertSearch InertCap 1
GA274 - Analysis of Tulobuterol Transdermal Tapes(Under the Condition of the draft for the Japanese Pharmacopoeia) -

GC InertSearch InertCap 1
GA273 - Analysis of Saccharin(Under the Condition of the PDG (Pharmacopeial Discussion Group) Stage 6 Drafts) -

GC InertSearch InertCap 17

Applications including "Draft"

LB902 - Analysis of Saxagliptin -

LB901 - Analysis of Saxagliptin -

LB900 - Analysis of Fesoterodine Fumarate -

LB899 - Analysis of Fesoterodine Fumarate -

GA352 - Analysis of Dipropylene Glycol -

LB896 - Analysis of Triptorelin Pamoate -

LB895 - Analysis of Venlafaxine hydrochloride -

LB891 - Analysis of Saxagliptin -

LB890 - Analysis of Saxagliptin -

LB889 - Analysis of Propyl gallate -

LB888 - Analysis of Propyl gallate -

LB887 - Analysis of Propyl gallate -

LB885 - Analysis of Voriconazole -

LB884 - Analysis of Voriconazole -

LB882 - Analysis of Paracetamol and Mefenamic acid -

LB881 - Analysis of Paracetamol and Mefenamic acid -

LB880 - Analysis of Paracetamol and Mefenamic acid -

LB879 - Analysis of Paracetamol and Mefenamic acid -

LB878 - Analysis of Mefenamic acid -

LB877 - Analysis of Mefenamic acid -

LB874 - Analysis of Captopril and Captopril Disulfide -

LB873 - Tacrolimus Extended-Release Capsules -

LB872 - Analysis of Febuxostat -

LB871 - Analysis of Febuxostat -

LB870 - Analysis of Febuxostat -

LB867 - Analysis of Febuxostat -

LB849 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LB848 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LB755 - Analysis of Oxaliplatin (Under the Condition of the draft for the Japanese Pharmacopoeia18th supplement II) -

LB671 - Analysis of Sucrose (Under the condition of the PDG (Pharmacopeial Discussion Group) Stage 2 Drafts) -

LB670 - Analysis of Sucrose (Under the condition of the PDG (Pharmacopeial Discussion Group) Stage 2 Drafts) -

LB641 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LB640 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LB635 - Analysis of Levetiracetam (Under the Condition of draft for USP) -

LB634 - Analysis of Rivaroxaban (Under the Condition of draft for USP, Rivaroxaban Tablets) -

LB633 - Analysis of Rivaroxaban (Under the Condition of draft for USP) -

LB628 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (7) 2-Pyrrolidone) -

LB627 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone and vinyl acetate) -

LB624 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LB623 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LT130 - Analysis of Anion Surfactants by LC/MS/MS -

LT052 - Analysis of Geniposide with a Photodiode Array Detection -

LB555 - Analysis of Mirtazapine (Under the Condition of draft for USP, Mirtazapine Compounded Oral Suspension, Veterinary) -

LB548 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LB547 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LB546 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LB545 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LB532 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets B) -

LB531 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets A) -

LB529 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc Granules) -

LB528 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc) -

LB527 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LB526 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LB525 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LB523 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LB520 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LB519 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LB512 - Analysis of Pioglitazone hydrochloride （Under the Condition of the draft for USP） -

LB510 - Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) -

LB508 - Analysis of Sitagliptin (Under the Condition of the draft for the Japanese Pharmacopoeia, Sitagliptin Phosphate Hydrate) -

LB489 - Analysis of Azosemide (Under the Condition of the draft for the Japanese Pharmacopoeia, Azosemide Tablets) -

LB476 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LB475 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LB474 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LB473 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB471 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB448 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) -

LB447 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) -

LB446 - Analysis of Hydrocortisone butyrate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB444 - Analysis of Pazufloxacin mesilate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB415 - Analysis of Methotrexate (Under the Condition of the draft for the Japanese Pharmacopoeia, Methotrexate Tablets) -

LB413 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB412 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB411 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB410 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LB409 - Analysis of Mesalazine (Under the Condition of the draft for the Japanese Pharmacopoeia, Mesalazine Extended-release Tablets) -

LB177 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 2-pyrrolidone) -

LB176 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone) -